WO2024236544 - PET TRACER COMPOUNDS FOR TRACING ALPHA-GALACTOSIDASE A AND REACTION INTERMEDIATES, AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2024/236544
Publication Date
21.11.2024
International Application No.
PCT/IB2024/054827
International Filing Date
17.05.2024
Title **
[English]
PET TRACER COMPOUNDS FOR TRACING ALPHA-GALACTOSIDASE A AND REACTION INTERMEDIATES, AND METHODS OF USE
[French]
COMPOSÉS TRACEURS POUR TEP DESTINÉS AU SUIVI D'ALPHA-GALACTOSIDASE A ET D'INTERMÉDIAIRES DE RÉACTION ET MÉTHODES D'UTILISATION
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
1-1, Doshomachi 4-chome
Chuo-ku
Osaka-shi, Osaka 541-0045, JP
Inventors
LOHITH, Talakad
c/o Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, Massachusetts 02139, US
MCQUADE, Paul
c/o Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, Massachusetts 02139, US
NARAYANAN, Sarav
c/o Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, Massachusetts 02139, US
ISLAM, Rizwana
c/o Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, Massachusetts 02139, US
KAITTANIS, Charalambos
c/o Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, Massachusetts 02139, US
Priority Data
63/502,761
17.05.2023
US
63/573,324
02.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2538 | |
| EPO | Filing, Examination | 15953 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 9360 |
Total: 29053 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
-galactosidase A gene therapy or after an enzyme replacement therapy.[French]
-galactosidase A ou après une thérapie de remplacement enzymatique.